Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.

The investigators want to

• evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and

• analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Details

• Lead Sponsor: Yonsei University
• Collaborator: Inje University
• Treatments: Antineoplastic Agents, Hormonal; Tamoxifen

Criteria

Inclusion Criteria:

• age ≥ 18 years

• Breast cancer patients who underwent surgery

Exclusion Criteria:

• None